



May 13, 2025

The Honorable Mike Johnson
Speaker of the House
United States House of Representatives
Washington, D.C. 20515

The Honorable John Thune
Majority Leader
United States Senate
Washington, D.C. 20510

Dear Mr. Speaker and Majority Leader Thune:


On behalf of the Coalition Against Socialized Medicine (CASM) and 23 partner organizations, we write to express **strong opposition** to the potential inclusion of a "Most Favored Nation" (MFN) pricing model in the forthcoming budget reconciliation package.

This policy would tie U.S. drug prices to those set by foreign governments. Many of these countries have socialist single-payer healthcare systems and impose strict price controls that delay or deny access to lifesaving treatments. Bringing those policies into our own healthcare system would threaten vulnerable patients, weaken American innovation, and replace market-driven competition with government-dictated prices.

For example, Medicaid already receives the lowest prices in the U.S. market. Manufacturers are required to offer discounts that routinely exceed 50%. Replacing that structure with MFN-based pricing would dramatically expand the number of drugs sold at a loss -- an outcome that is already occurring for some medicines today.

If manufacturers determine that selling to Medicaid at artificially low prices is no longer sustainable, they could be forced to withdraw from the program. That would disrupt access to medicines for patients who rely on Medicaid and trigger spillover effects in Medicare Part B, which requires manufacturers to participate in Medicaid for their products to be reimbursed. As a result, seniors and low-income patients could face higher costs or lose access to treatments for cancer, rare diseases, and other serious conditions.

MFN would also undermine one of President Trump's most important achievements: bringing pharmaceutical investment and manufacturing back to the United States. Since his election, companies have already announced roughly \$230 billion in new U.S.-based manufacturing and research projects. Adopting foreign price controls would halt this progress and potentially hand a strategic advantage to competitors like [China](#) and [India](#), which have invested heavily in their domestic biotech industries in recent years.





TRADE ALLIANCE
to Promote Prosperity

The U.S. biopharmaceutical industry is one of the [strongest sectors](#) of the American economy. Nearly [two-thirds](#) of all new medicines developed over the past decade were created by American companies. That leadership is possible because our system rewards innovation. Replacing it with a model based on foreign government price-setting would only discourage investment in new cures.

There are smarter ways to reduce costs. Congress should begin by rooting out the waste, fraud, and abuse that drive up spending in both [Medicaid](#) and [Medicare](#). Targeted reforms include requiring more frequent eligibility checks, ending special treatment for able-bodied adults, and stopping states from using provider taxes to inflate federal payments. These steps could save more than \$1 trillion while protecting access for the truly needy.

Congress should also rein in the corporate middlemen who drive up prices while providing no real value for patients. Pharmacy benefit managers (PBMs) often pocket large rebates while patients pay more at the pharmacy counter. Any serious approach to lowering costs must include transparency and accountability for PBMs.

At the same time, lawmakers must address the very real problem of foreign freeloading. Wealthy countries routinely underpay for American-developed medicines while enjoying the benefits of our innovation ecosystem. Congress should take steps to ensure that our trading partners contribute their fair share rather than placing the full burden on U.S. patients and taxpayers. That would be a true "America First" reform.

We also urge you to consider the [measurable damage](#) already caused by Biden-era drug price control policies. The MFN model would build on those mistakes, making it harder for American companies to compete and innovate and for patients to get the care they need.

This is a critical moment. The MFN model is not real reform. It is a deeply flawed proposal that would put foreign bureaucrats in charge of decisions that should be made by American patients and doctors. We respectfully urge you to reject this policy and support solutions that protect innovation, strengthen access and affordability, and put America first.

Thank you for your consideration.

Sincerely,

Andrew Langer
Executive Director
Coalition Against Socialized Medicine

James L. Martin
Founder & Chairman
60 Plus Association

Saul Anuzis
President
60 Plus Association

Tim Chapman
President
Advancing American Freedom

Phil Kerpen
President
American Commitment

Tirzah Duren
President
American Consumer Institute

Dee Stewart
President
Americans for a Balanced Budget

Ryan Ellis
President
Center for a Free Economy

Anthony Zagotta
President
Center for American Principles

Jeffrey Mazzella
President
Center for Individual Freedom

Ginevra Joyce-Myers
Executive Director
Center for Innovation and Free
Enterprise

Peter Pitts
President
Center for Medicine in the Public
Interest

James Edwards
Founder & Executive Director
Conservatives for Property Rights

Matthew Kandrach
President
Consumer Action for a Strong Economy

Frederik Roeder
Managing Director
Consumer Choice Center

Elizabeth Hicks
U.S. Affairs Analyst
Consumer Choice Center

George Landrith
President
Frontiers of Freedom

Mario H. Lopez
President
Hispanic Leadership Fund

Jerry Rogers
Vice President
Institute for Liberty

Charlie Sauer
President
Market Institute

Pete Sepp
President
National Taxpayers Union

Sally Pipes
President
Pacific Research Institute

Wayne Winegarden
Sr. Fellow and Director of Center for
Medical Economics and Innovation
Pacific Research Institute

John Tamny
President
Parkview Institute

Karen Kerrigan
President & CEO
Small Business & Entrepreneurship
Council

David Williams
President
Taxpayers Protection Alliance

Kent Kaiser
Executive Director
Trade Alliance to Promote Prosperity

Cc:

The Honorable Bill Cassidy, United States Senate

The Honorable Mike Crapo, United States Senate

The Honorable Brett Guthrie, United States House of Representatives